<?xml version="1.0" encoding="UTF-8"?>
<collection xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd" xmlns="http://www.loc.gov/MARC21/slim">
 <record>
  <leader>00000ctm a22000003a 4500</leader>
  <controlfield tag="001">UP-1685523046126318428</controlfield>
  <controlfield tag="003">Buklod</controlfield>
  <controlfield tag="005">20170814173749.0</controlfield>
  <controlfield tag="006">m    |o  d |      </controlfield>
  <controlfield tag="007">ta</controlfield>
  <controlfield tag="008">170814s2017    xx     d     r    |||| u|</controlfield>
  <datafield tag="035" ind1=" " ind2=" ">
   <subfield code="a">(iLib)UPMNL-00015498145</subfield>
  </datafield>
  <datafield tag="040" ind1=" " ind2=" ">
   <subfield code="a">UPM PHARM</subfield>
   <subfield code="e">rda</subfield>
  </datafield>
  <datafield tag="041" ind1=" " ind2=" ">
   <subfield code="a">eng</subfield>
  </datafield>
  <datafield tag="090" ind1=" " ind2="0">
   <subfield code="a">LG 993.5 2017 P5</subfield>
   <subfield code="b">L44</subfield>
  </datafield>
  <datafield tag="100" ind1="1" ind2=" ">
   <subfield code="a">Legaspi, Donato Jr. D.</subfield>
   <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="245" ind1="0" ind2="0">
   <subfield code="a">Development of predictive PBPK model for extended-release metformin tablets through Simcyp software</subfield>
   <subfield code="c">Donato D. Legaspi Jr., Frances Lois U. Ngo, Imma Coney P. Olayan ; adviser,  Bryan Paul I. Bulatao.</subfield>
  </datafield>
  <datafield tag="264" ind1=" " ind2="1">
   <subfield code="a">​​​​​​​​​​Manila: Department of Industrial Pharmacy, College of Pharmacy, University of the Philippines Manila</subfield>
   <subfield code="c">2017. ​​</subfield>
  </datafield>
  <datafield tag="300" ind1=" " ind2=" ">
   <subfield code="a">vii, 71 leaves</subfield>
   <subfield code="c">28 cm.</subfield>
  </datafield>
  <datafield tag="336" ind1=" " ind2=" ">
   <subfield code="a">​​​​text</subfield>
   <subfield code="2">rdacontent</subfield>
  </datafield>
  <datafield tag="337" ind1=" " ind2=" ">
   <subfield code="a">unmediated</subfield>
   <subfield code="2">rdamedia</subfield>
  </datafield>
  <datafield tag="338" ind1=" " ind2=" ">
   <subfield code="a">volume</subfield>
   <subfield code="2">rdacarrier</subfield>
  </datafield>
  <datafield tag="500" ind1=" " ind2=" ">
   <subfield code="a">Available to the general public.</subfield>
  </datafield>
  <datafield tag="502" ind1=" " ind2=" ">
   <subfield code="a">​​​​​​Thesis (Bachelor of Science in Industrial Pharmacy)--University of the Philippines Manila, June 2017.</subfield>
  </datafield>
  <datafield tag="520" ind1=" " ind2=" ">
   <subfield code="a">Physiologically Based Pharmacokinetic (PBPK) models integrate the physiological, physicochemical and biochemical processes that determine the pharmacokinetic behavior of a compound such as metformin. PBPK Modelling using the Simcyp software can be applied as a method for requesting biowaivers. Modelling can be expanded to extended release formulations requiring expensive and tedious in vivo studies. Modelling using in vivo data from literature instead is another application of Simcyp. The objective of the study was to develop a drug-specific PBPK model that can be used to correlate in-vivo in-vitro performance of metformin ER tablets. Metformin specific PBPK model was developed from pharmacokinetic parameters from literature and in vivo data from Balan et al. (2001). Dissolution was performed to two brands of 500 mg metformin ER tablets available in the Philippines to examine the internal validity of the model. Point-to-point relationship was evaluated to determine if the model achieved level A correlation by computing for the prediction error (%PE). Resulting %PE of the model were greater than the 10% criteria indicative of a Level A correlation. Therefore, the model developed has poor internal predictability and must be further refined. Additional pharmacokinetic parameters such as data on the OCT1 and OCT3 protein transporters crucial in metformin absorption is recommended to be included in the input parameters. The use of clinical in vivo data from literature with subjects closest to the genetic makeup of a Filipino can simulate a more appropriate data for the purpose of products in the count.</subfield>
  </datafield>
  <datafield tag="650" ind1="1" ind2="7">
   <subfield code="a">Metformin.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
   <subfield code="a">Ngo, Frances Lois U.</subfield>
   <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
   <subfield code="a">Olayan, Imma Coney P.</subfield>
   <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
   <subfield code="a">Bulatao, Bryan Paul I.</subfield>
   <subfield code="e">thesis adviser.</subfield>
  </datafield>
  <datafield tag="905" ind1=" " ind2=" ">
   <subfield code="a">FI</subfield>
  </datafield>
  <datafield tag="905" ind1=" " ind2=" ">
   <subfield code="a">UP</subfield>
  </datafield>
  <datafield tag="852" ind1="0" ind2=" ">
   <subfield code="a">UPMNL</subfield>
   <subfield code="b">PHARM</subfield>
   <subfield code="h">LG 993.5 2017 P5</subfield>
   <subfield code="i">L44</subfield>
  </datafield>
  <datafield tag="942" ind1=" " ind2=" ">
   <subfield code="a">Thesis</subfield>
  </datafield>
 </record>
</collection>
